Abstract
Coronary artery disease (CAD) is the most important cause of death in the industrialized world. After experimental myocardial infarction, numerous dilated vessels appear in the border zone between the infarct and noninfarct areas. Angiogenic therapy has been widely regarded as an attractive approach for both treating CAD and enhancing arterioprotective functions of the endothelium. In this report, we critically review the evidence supporting the regulation of angiogenesis and angiogenic factors by cardiovascular medications such as statins, cholesterol ester transfer protein inhibitor, angiotensin II type 1 receptor blocker, angiotensin-converting enzyme inhibitor and calcium channel blocker, etc. Furthermore, in patients with CAD, vascular growth (vasculogenesis), capillary network growth (angiogenesis) and collateral artery growth (arteriogenesis), may be important. Current evidence from clinical trials on these therapies suggests that the development of coronary collateral circulation is likely to be a viable therapeutic strategy for CAD, while adaptation to chronic coronary stenosis can proceed. Many studies have suggested that newly developed strategies which include the administration of angiogenic growth factors and the transplantation of bone marrow-derived angioblasts are beneficial for the ischemic heart. Our assessment of the evidence in this review leads us to conclude that the development of collateral circulation using conventional cardiovascular medications may also play a critical role and needs to be reconsidered in the treatment of patients with CAD.
Keywords: Coronary artery disease, endothelium, statins, angiotensin II type 1 receptor blocker, angiotensin converting enzyme inhibitor, calcium channel blocker, coronary collateral circulation
Current Pharmaceutical Design
Title: Regulation of Angiogenesis and Angiogenic Factors by Cardiovascular Medications
Volume: 13 Issue: 20
Author(s): Shin-ichiro Miura and Keijiro Saku
Affiliation:
Keywords: Coronary artery disease, endothelium, statins, angiotensin II type 1 receptor blocker, angiotensin converting enzyme inhibitor, calcium channel blocker, coronary collateral circulation
Abstract: Coronary artery disease (CAD) is the most important cause of death in the industrialized world. After experimental myocardial infarction, numerous dilated vessels appear in the border zone between the infarct and noninfarct areas. Angiogenic therapy has been widely regarded as an attractive approach for both treating CAD and enhancing arterioprotective functions of the endothelium. In this report, we critically review the evidence supporting the regulation of angiogenesis and angiogenic factors by cardiovascular medications such as statins, cholesterol ester transfer protein inhibitor, angiotensin II type 1 receptor blocker, angiotensin-converting enzyme inhibitor and calcium channel blocker, etc. Furthermore, in patients with CAD, vascular growth (vasculogenesis), capillary network growth (angiogenesis) and collateral artery growth (arteriogenesis), may be important. Current evidence from clinical trials on these therapies suggests that the development of coronary collateral circulation is likely to be a viable therapeutic strategy for CAD, while adaptation to chronic coronary stenosis can proceed. Many studies have suggested that newly developed strategies which include the administration of angiogenic growth factors and the transplantation of bone marrow-derived angioblasts are beneficial for the ischemic heart. Our assessment of the evidence in this review leads us to conclude that the development of collateral circulation using conventional cardiovascular medications may also play a critical role and needs to be reconsidered in the treatment of patients with CAD.
Export Options
About this article
Cite this article as:
Shin-ichiro Miura and Keijiro Saku , Regulation of Angiogenesis and Angiogenic Factors by Cardiovascular Medications, Current Pharmaceutical Design 2007; 13 (20) . https://dx.doi.org/10.2174/138161207781039724
DOI https://dx.doi.org/10.2174/138161207781039724 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biological Active Ingredients of Traditional Chinese Herb Astragalus membranaceus on Treatment of Diabetes: A Systematic Review
Mini-Reviews in Medicinal Chemistry Soluble Forms of RAGE in Human Diseases: Clinical and Therapeutical Implications
Current Medicinal Chemistry Iron and Iron Chelators: A Review on Potential Effects on Skin Aging
Current Aging Science Prostaglandin E<sub>2</sub> Receptor 4 (EP4): A Promising Therapeutic Target for the Treatment of Cancer and Inflammatory Diseases
Current Chemical Biology AMPK - Activated Protein Kinase and its Role in Energy Metabolism of the Heart
Current Cardiology Reviews Clinical Application of Tissue Doppler Imaging in Coronary Artery Diseases and Heart Failure
Recent Patents on Medical Imaging Obstructive Sleep Apnea as an Independent Stroke Risk Factor: Possible Mechanisms
Current Molecular Medicine UPP mediated Diabetic Retinopathy via ROS/PARP and NF-κB inflammatory factor pathways.
Current Molecular Medicine Targeting Heme Oxygenase-1 in Vascular Disease
Current Drug Targets The Influence of Exercise Upon Cardiac Biomarkers: A Practical Guide for Clinicians and Scientists
Current Medicinal Chemistry Antiplatelet Therapy in TAVI: Current Clinical Practice and Recommendations
Current Pharmaceutical Design The Vascular Endothelin System in Hypertension - Recent Patents and Discoveries
Recent Patents on Cardiovascular Drug Discovery The Impact of Small Heat Shock Proteins (HspBs) in Alzheimer’s and Other Neurological Diseases
Current Pharmaceutical Design Stem Cell Aging and Age-Related Cardiovascular Disease: Perspectives of Treatment by Ex-vivo Stem Cell Rejuvenation
Current Drug Targets Harvesting New Therapeutic Avenues with Stem Cell Applications
Current Neurovascular Research The Effect of Acute Hypoxia on Excitability in the Heart and the L-Type Calcium Channel as a Therapeutic Target
Current Drug Discovery Technologies Radial Approach for Percutaneous Coronary Intervention
Reviews on Recent Clinical Trials Vascular Disease and Insulin-Like Growth Factor-1
Vascular Disease Prevention (Discontinued) Pharmacogenomics of Cardiovascular Complications in Diabetes and Obesity
Recent Patents on Biotechnology Potential Biomarkers for Depression Associated with Coronary Artery Disease: A Critical Review
Current Molecular Medicine